Myopharm
Clinical-stage Australian biopharmaceutical company developing targeted therapies and clinically validated consumer health products for metabolic and inflammatory chronic diseases, with R&D, regulatory and manufacturing activities focused on therapies for type 2 diabetes and related indications.
Industries
Nr. of Employees
small (1-50)
Myopharm
Levels 1, 2 & 3, 60 Martin Place, Sydney NSW 2000, Australia
Patents
Products
TriGlytza (RK-01) — clinical-stage therapeutic candidate
A drug candidate developed to preserve or restore pancreatic beta-cell function and reduce insulin resistance in type 2 diabetes through targeting inflammatory mediators and related signalling pathways.
OMNI-D — pre-meal medical nutrition product
A pre-meal nutritional formulation composed of protein and soluble fibre designed to slow gastric absorption and reduce postprandial blood glucose excursions; described as clinically validated for people with type 2 diabetes.
OMNI-E — electrolyte product
An electrolyte formulation with calcium and natural salts, presented with no added sugar and intended as a consumer health product.
TriGlytza (RK-01) — clinical-stage therapeutic candidate
A drug candidate developed to preserve or restore pancreatic beta-cell function and reduce insulin resistance in type 2 diabetes through targeting inflammatory mediators and related signalling pathways.
OMNI-D — pre-meal medical nutrition product
A pre-meal nutritional formulation composed of protein and soluble fibre designed to slow gastric absorption and reduce postprandial blood glucose excursions; described as clinically validated for people with type 2 diabetes.
OMNI-E — electrolyte product
An electrolyte formulation with calcium and natural salts, presented with no added sugar and intended as a consumer health product.
Services
Joint research and clinical study collaborations with universities, clinical institutes and industry partners to advance preclinical and clinical programs.
Joint research and clinical study collaborations with universities, clinical institutes and industry partners to advance preclinical and clinical programs.
Expertise Areas
- Clinical trial management (Phase II, multi-site)
- Regulatory strategy and IND management
- Translational research and biomarker analysis
- Diabetes therapeutics and metabolic disease R&D
Key Technologies
- Clinical trial platforms (Phase II)
- Regulatory submission workflows (IND)
- Biomarker-driven endpoint analysis
- Preclinical animal models
News & Updates
Announcement of a multi-year partnership with a national diabetes organisation to support research or program activities.
Press release reporting preclinical data indicating a reduction in HbA1c in preclinical models.
Company profile and work on beta-cell centric therapeutics featured at a major diabetes scientific meeting in 2024.
Announcement of a multi-year partnership with a national diabetes organisation to support research or program activities.
Press release reporting preclinical data indicating a reduction in HbA1c in preclinical models.
Company profile and work on beta-cell centric therapeutics featured at a major diabetes scientific meeting in 2024.